Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Metformin is considered to be one of the most effective therapeutics for the treatment of type 2 diabetes (T2D) since it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain, or posing a risk of hypoglycemia(1,2). For over half a century, this agent...

Full description

Saved in:

Bibliographic Details
Main Authors:	Madiraju, Anila K., Erion, Derek M., Rahimi, Yasmeen, Zhang, Xian-Man, Braddock, Demetrios, Albright, Ronald A., Prigaro, Brett J., Wood, John L., Bhanot, Sanjay, MacDonald, Michael J., Jurczak, Michael, Camporez, Joao-Paulo, Lee, Hui-Young, Cline, Gary W., Samuel, Varman T., Kibbey, Richard G., Shulman, Gerald I.
Format:	Artigo
Language:	Inglês
Published:	2014
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4074244/ https://ncbi.nlm.nih.gov/pubmed/24847880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature13270
Tags:	Add Tag No Tags, Be the first to tag this record!

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Similar Items